Search research articles
Contact Us
Filters
Showing results (61-70 of 157) with videos related to
Page
of 16
Sort By:
Journal of Cell Science. Supplement
|
January 1, 1985
The use of anti-synthetic peptide antibodies to study the v-erb B protein from chicken and rat cells transformed by avian erythroblastosis virus
W J Gullick, J J Marsden, J Downward, et al.
European Journal of Biochemistry
|
July 15, 1986
Antibodies to the ATP-binding site of the human epidermal growth factor (EGF) receptor as specific inhibitors of EGF-stimulated protein-tyrosine kinase activity
W J Gullick, J Downward, J G Foulkes, et al.
International Journal of Cancer
|
March 20, 1998
Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin
M Schmidt, P Reiser, D Hills, et al.
Cancer Research
|
April 5, 2000
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers
R Srinivasan, C E Gillett, D M Barnes, et al.
The Journal of Biological Chemistry
|
September 5, 1993
Characterization of high and low molecular weight forms of amphiregulin that differ in glycosylation and peptide core length. Evidence that the NH2-terminal region is not critical for bioactivity
G R Johnson, S A Prigent, W J Gullick, et al.
Lancet (London, England)
|
July 11, 1987
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification
D J Venter, N L Tuzi, S Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 1999
Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer
R Srinivasan, E Benton, F McCormick, et al.
Oncogene
|
May 26, 1999
Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation
G M Morley, M Uden, W J Gullick, et al.
Oncogene
|
October 1, 1993
Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo
F J Lofts, H C Hurst, M J Sternberg, et al.
The Journal of Biological Chemistry
|
September 22, 1995
Binding of Shc to the NPXY motif is mediated by its N-terminal domain
S A Prigent, T S Pillay, K S Ravichandran, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 157) with videos related to
Sort By:
Page
of 16
Journal of Cell Science. Supplement
|
January 1, 1985
The use of anti-synthetic peptide antibodies to study the v-erb B protein from chicken and rat cells transformed by avian erythroblastosis virus
W J Gullick, J J Marsden, J Downward, et al.
European Journal of Biochemistry
|
July 15, 1986
Antibodies to the ATP-binding site of the human epidermal growth factor (EGF) receptor as specific inhibitors of EGF-stimulated protein-tyrosine kinase activity
W J Gullick, J Downward, J G Foulkes, et al.
International Journal of Cancer
|
March 20, 1998
Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin
M Schmidt, P Reiser, D Hills, et al.
Cancer Research
|
April 5, 2000
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers
R Srinivasan, C E Gillett, D M Barnes, et al.
The Journal of Biological Chemistry
|
September 5, 1993
Characterization of high and low molecular weight forms of amphiregulin that differ in glycosylation and peptide core length. Evidence that the NH2-terminal region is not critical for bioactivity
G R Johnson, S A Prigent, W J Gullick, et al.
Lancet (London, England)
|
July 11, 1987
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification
D J Venter, N L Tuzi, S Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 1999
Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer
R Srinivasan, E Benton, F McCormick, et al.
Oncogene
|
May 26, 1999
Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation
G M Morley, M Uden, W J Gullick, et al.
Oncogene
|
October 1, 1993
Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo
F J Lofts, H C Hurst, M J Sternberg, et al.
The Journal of Biological Chemistry
|
September 22, 1995
Binding of Shc to the NPXY motif is mediated by its N-terminal domain
S A Prigent, T S Pillay, K S Ravichandran, et al.
Page
of 16